775 related articles for article (PubMed ID: 18591545)
21. DNA repair deficiency as a therapeutic target in cancer.
Martin SA; Lord CJ; Ashworth A
Curr Opin Genet Dev; 2008 Feb; 18(1):80-6. PubMed ID: 18343102
[TBL] [Abstract][Full Text] [Related]
22. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
23. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
[TBL] [Abstract][Full Text] [Related]
24. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
25. Making the best of PARP inhibitors in ovarian cancer.
Banerjee S; Kaye SB; Ashworth A
Nat Rev Clin Oncol; 2010 Sep; 7(9):508-19. PubMed ID: 20700108
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Sandhu SK; Yap TA; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
[TBL] [Abstract][Full Text] [Related]
28. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
29. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
Aly A; Ganesan S
J Mol Cell Biol; 2011 Feb; 3(1):66-74. PubMed ID: 21278454
[TBL] [Abstract][Full Text] [Related]
30. Role of PARP inhibitors in cancer biology and therapy.
Davar D; Beumer JH; Hamieh L; Tawbi H
Curr Med Chem; 2012; 19(23):3907-21. PubMed ID: 22788767
[TBL] [Abstract][Full Text] [Related]
31. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
Gaziev AI
Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathways: targeting PARP in cancer treatment.
Do K; Chen AP
Clin Cancer Res; 2013 Mar; 19(5):977-84. PubMed ID: 23269547
[TBL] [Abstract][Full Text] [Related]
33. Mechanism for Synthetic Lethality in BRCA-Deficient Cancers: No Longer Lagging Behind.
van Wietmarschen N; Nussenzweig A
Mol Cell; 2018 Sep; 71(6):877-878. PubMed ID: 30241603
[TBL] [Abstract][Full Text] [Related]
34. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
35. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
36. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Farmer H; McCabe N; Lord CJ; Tutt AN; Johnson DA; Richardson TB; Santarosa M; Dillon KJ; Hickson I; Knights C; Martin NM; Jackson SP; Smith GC; Ashworth A
Nature; 2005 Apr; 434(7035):917-21. PubMed ID: 15829967
[TBL] [Abstract][Full Text] [Related]
37. Exploiting replication gaps for cancer therapy.
Cong K; Cantor SB
Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
[TBL] [Abstract][Full Text] [Related]
38. Poly(ADP-ribose) polymerase inhibitors as cancer therapy.
Hilton JF; Hadfield MJ; Tran MT; Shapiro GI
Front Biosci (Landmark Ed); 2013 Jun; 18(4):1392-406. PubMed ID: 23747892
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.
Helleday T; Bryant HE; Schultz N
Cell Cycle; 2005 Sep; 4(9):1176-8. PubMed ID: 16123586
[TBL] [Abstract][Full Text] [Related]
40. Development of PARP inhibitors in oncology.
Rodon J; Iniesta MD; Papadopoulos K
Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
